About this trial
A prospective, single-center, single-group follow-up study of transcatheter aortic valve replacement with A² Flex and commissural alignment technology in severe aortic stenosis by Peijia Medical
Eligibility criteria
Qualifiers
Patients who are willing to participate and sign the informed consent and can cooperate with the whole trial process;
Age ≥60 years old;
Patients with severe calcified aortic stenosis confirmed by echocardiography (trans-aortic valve flow velocity ≥ 4.0m /s, or trans-active valvular pressure difference ≥40mmHg (1mmHg=0.133kPa), or aortic valve orientation area < 0.8cm2, or effective aortic valve orifice the product index is < 0.5cm2/m2);
The cardiac team (at least two specialists in cardiovascular surgery) assessed the patient as unsuitable for routine surgery ;
Disqualifiers
The left and right coronary ostiums originate from the junctional zone or from both coronary ostiums;
previous CABG history;
Coronary ostial lesions(PCI or not);
Prior aortic valve prosthesis implantation (interventional/surgical, bioprosthetic/mechanical);
Trial design
Treatments tested in this trial
- transcatheter aortic valve replacement in severe aortic stenosis
Treatment groups
Sponsors and collaborators
Peijia Medical Technology (Suzhou) Co., Ltd.
Lead sponsor
Shanghai Zhongshan Hospital
Collaborator